Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance, pharmacokinetics, and metabolism study of oral [14C]-zipalertinib in healthy adult male subjects
NL-OMON59249Phase 1Completed
- Sponsor
- Taiho Oncology
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of zipalertinib, sponsored by Taiho Oncology. Started Jul 2023; status: completed.
02
Drugs
zipalertinib
Beyond the preview
Go deeper on NL-OMON59249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59249.